Navigation Links
Cytotoxic in Medical News

Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients

... selectively direct and activate an individual's cytotoxic T-cells, the body's most potent killer cells, to ... These cytolytic synapses enable the delivery of cytotoxic proteins from T-cells into tumor cells, ... antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is ...

Micromet's BiTE(R) Antibodies Reveal Unique Mode of Action

... antibodies are designed to transiently connect cytotoxic T cells with cancer cells leading to a tightly ... elimination of cancer cells. In this process, cytotoxic T cells are activated, which causes them to ... These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ...

4th ESU master class on medical treatment for urological cancer held in Barcelona, Spain

... module 2 'Immunotherapy and targeted therapies' and module 3 'Systemic cytotoxic chemotherapy and palliation'. Each module comprises short ... treatment, chemoprevention, immunotherapy, targeted therapies and systemic cytotoxic chemotherapy and palliation, supplemented with case discussions and ...

Early treatment of systemic onset JIA with anakinra restores the IL-18 response

... function which compromises their immune systems, since NK cells (a type of cytotoxic lymphocyte, or white blood cell, that is capable of killing infected ... patients flared following anakinra treatment. *NK cells are a type of cytotoxic lymphocyte that constitute a major component of the innate immune system. ...

European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors

... In addition to the new presentations, TEMODAL (temozolomide), a cytotoxic agent, is currently approved in oral form as 5mg, 20mg, 100mg, 140mg, 180mg and 250mg capsules in Europe. cytotoxic agents are designed to impact the replication of cells that divide ...

Telik Announces Fourth Quarter and 2008 Year End Financial Results and 2009 Financial Guidance

... and Telik's two leading preclinical oncology drug candidates: a cytotoxic prodrug, TLK58747, and dual Aurora-VEGFR inhibitor, TLK60404. The company ... SCIN, 3) advancing its two leading preclinical oncology drug candidates: a cytotoxic prodrug, TLK58747, and dual Aurora-VEGFR kinase inhibitor, TLK60404, 4) ...

Craig W. Philips Takes Helm at CTI

... activity and has demonstrated activity in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical, ... activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical ...

Micromet, Inc. Reports First Quarter 2008 Financial Results

... represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune ... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ...

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme

... MP470, its clinical-stage multi-targeted tyrosine kinase inhibitor, is cytotoxic to glioblastoma multiforme cell lines (Abstract No. 178). Activity was ... synergistic with radiation. Glioblastoma multiforme is often resistant to cytotoxic therapies and radiation, due to increased DNA repair and the inhibition of ...

Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia

... T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a ... represent a new class of antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in ...

Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects

... Non-toxic Non-irritating Water-soluble Safe for all skin types Produces no harmful by-products Has no cytotoxic effect Lumixyl products are made exclusively for dermatologists, plastic surgeons and skin oriented aesthetic physicians. The products ...

Bionovo Presents Positive Results from Phase 1B Trial of Bezielle for Metastatic Breast Cancer

... support that Bezielle is safe and well-tolerated, with early signs of clinical efficacy. Safety Analysis In comparison to other oral cytotoxic agents, Bezielle was extremely safe and well tolerated. No drug-related deaths or serious adverse events occurred during the study, and 94% of all ...

Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patients

... a trial testing a combination of two molecularly targeted agents in patients 70 years or older. The team reasoned that a combination lacking standard cytotoxic agents may be better tolerated by these patients, potentially without comprising efficacy. "We looked for a regimen that had few side effects, would ...

Driven by Launch of Emerging Therapies, Overall Prostate Cancer Drug Market Will Increase by $2 Billion Through 2018

... agents such as Avastin," said Decision Resources Analyst Andrew Merron, Ph.D. "The use of Taxotere to treat patients not previously receiving cytotoxic agents will increase over the next decade as oncologists are expected to take a more prominent role in the treatment of prostate cancer patients." ...

Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding Trabectedin for Relapsed Ovarian Cancer

... evaluation. The final decision regarding approval of the drug will be made by the FDA. About Trabectedin Trabectedin is a novel cytotoxic antitumor agent that was originally derived from the marine tunicate, Ecteinascidia turbinata. The compound is now produced synthetically. ...

New Compounding Pharmacy Videos Provide Product Information, Teach Safety

... Video informs and educates potential and existing users of barrier isolators on the following topics:   Introduction Risks Involving cytotoxic Drug Preparation USP Guidelines & Requirements Types of isolators How Isolators Work Safe Use of Pharmacy Isolators Cleaning & ...

Access Pharmaceuticals Announces Initiation of Two New Cobalamin(TM) Oral Insulin Drug Delivery Collaborations

... as the demand for vitamin B12 increases in many disease states." The ability of the Cobalamin technology to increase the efficacy of a cytotoxic drug through enhanced delivery to tumor cells was demonstrated in a preclinical model. This work was presented by Access at a major scientific ...

CEL-SCI Expands Testing of Its Vaccine to Determine Efficacy Against More Virulent Strain of H1N1 Swine and Other Influenza Viruses

... the development of T-cell function with primarily effector T-cell functions (T Lymphocyte; helper/effector T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). The L.E.A.P.S. vaccine constructs are chimeric peptides which combine antigen specificity with immune response modulation. ...

Ortho Biotech Oncology Research & Development Announces Collaboration with National Cancer Institute to Develop Novel Cell Therapies to Treat Cancer

... proprietary adoptive immunotherapeutic approach that uses tumor antigens and other materials to stimulate T cells from a patient's blood to become cytotoxic T Lymphocytes (CTLs), which recognize and attack tumor cells. Early clinical results show that this technology holds promise in melanoma patients and ...

Asymchem Announces sFDA Certification for Drug Product Manufacturing

... support phase 1 and phase 2 clinical studies. Separate facility of similar scale exists for manufacture of dosage forms containing highly potent or cytotoxic compounds. Meanwhile, a much larger drug product facility for commercial manufacturing is being built and expected to be operational by 2Q 2010. ...

Vaccine shows therapeutic promise against advanced melanoma

... known as gp100:209-217 (200M), works by stimulating patients' T cells, known for controlling immune responses. "This vaccine activates the body's cytotoxic T cells to recognize antigens on the surface of the tumor. The T cells then secrete enzymes that poke holes in the tumor cell's membrane, causing it ...

Experts Optimistic About Melanoma Vaccine

... The vaccine, called gp100:209-217 (200M), works by stimulating T-cells, which control immune response. "This vaccine activates the body's cytotoxic T-cells to recognize antigens on the surface of the tumor," Hwu said. "The T-cells then secrete enzymes that poke holes in the tumor cell's membrane, ...

Study shows drug combination improves outcome for advanced non-small cell lung cancer

... Dr. Miller added. In total, 768 patients were randomized to receive bevacizumab plus erlotinib or bevacizumab plus placebo after initial cytotoxic chemotherapy with bevacizumab. There was a 29 percent reduction in the risk of progression for those patients treated with erlotinib, and the median ...

Immunologists identify biochemical signals that help immune cells remember how to fight infection

... in promoting the development of a group of immune cells employed as tactical assassins. In their initial response, these immune cells, known as cytotoxic T lymphocytes, or CTLs, kill cells infected with pathogens. They also provide long-term protection against pathogens by "remembering" which proteins ...

Sanofi-aventis Announces Good First-quarter 2009 Performance

... half of 2008. In the United States, the product posted 2.9% growth in net sales to euro 197 million. Net sales of Eloxatin (R) , the leading cytotoxic agent in the colorectal cancer market as an adjuvant and as first line treatment in the metastatic phase, were up 3.0% at euro 266 million in the ...

Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors

... which is involved in a majority of human tumors, the nanoparticles hinder the multiplication of cancerous cells and predispose those cells to the cytotoxic effects of chemotherapeutic drugs. The team also modified the polymer to increase drug loading 20 fold, which overcomes a current drawback in ...

USC researchers develop new drug to target tumor cells and blood vessels

... the interior surface of blood vesselsfrom human nonmalignant brain and glioma tissues and treating them with DMC. They found that the drug was cytotoxic to tumor-associated endothelial cells and suppressed cell proliferation and migration without apparent toxic effects to normal tissues. Drug therapy ...

HIV handicaps itself to escape immune system pressure

... genes encode molecules that display fragments of viral proteins, known as epitopes, on the surface of infected cells. When white blood cells known as cytotoxic T lymphocytes (CTLs) spot certain combinations of HLA molecules and viral epitopes, they attack the infected cells. The authors show that a set ...

GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US

... drive the cancer growth," said Debasish Roychowdhury, MD, Head, Medicines Development, GSK Oncology. "If approved the combination could provide a cytotoxic chemotherapy-free option for these patients and we look forward to working with regulatory agencies to advance the availability of this regimen as a ...

Beating a Global Killer: HIV/AIDS

... helper Th-1 cells' expression of elaborate cytokines INFy, IL-2, which selectively promote cell-mediated immune response and subsequently stimulate cytotoxic lymphocytes. These lymphocytes have a prominent role in the host's immunologic response to HIV infection. Proteins encoded by these pathogens enter ...

Brain tumor treatment may increase number of cancer stem-like cells

... March 6th issue of the journal Cell Stem Cell , provides valuable insight into the molecular mechanisms that enable cancer stem-like cells to escape cytotoxic treatment and repopulate the tumor. Glioblastoma multiforme is the most prevalent and aggressive form of primary brain tumor and is notoriously ...

April 2009 Declared National Safe Handling Awareness Month

... illnesses - will continue to elevate risk of exposure.(2) Two separate studies investigating the toxicity in healthcare personnel who handle cytotoxic (hazardous) drugs revealed a 40-50 percent increased risk for miscarriage . A total of 7094 pregnancies of 2976 pharmacy and nursing staff were ...

Stem cells: Deathly awakening by interferon

... an awakening of the stem cells. The investigators obtained further proof of the effect of interferon-alpha using a drug called 5-fluorouracil, a cytotoxic substance frequently used for treating breast or bowel cancer. Dormant stem cells are resistant to the drug, which unfolds its effect only during ...

Sanofi-aventis Delivers 2008 Results Above Guidance

... in the fourth quarter and by 14.9% (to EUR 142 million) over the full year. In the United States, net sales of Eloxatin (R) , the leading cytotoxic agent in the colorectal cancer market as an adjuvant and in the metastatic phase, rose by 6.9% to EUR 265 million in the fourth quarter and by 6.2% ...

24th Annual EAU Congress highlights many new developments

... prostate cancer. Dr. Gleave will be discussing the status of several novel agents in clinical trials either as single agents or in combination with cytotoxic chemotherapy, including the androgen receptor, endothelin receptor, and molecular chaperones. Dr. Smith from Boston (U.S.) is keen on presenting ...

Bionovo Announces Presentation at the National Cancer Institute

... Institute's Office of Cancer Complementary and Alternative Medicine's (OCCAM) monthly lecture series. The title of the presentation is "Selective cytotoxic Activity of BZL 101 Towards Cancer Cells and Anti-Tumor Effects in Patients with Advanced Breast Cancer," and will be presented by Dr. Emma ...

Green tea may negate the effects of a common cancer therapy

... other natural supplements to complement their therapeutic regimens. We wanted to better understand how the compounds in green tea interact with a cytotoxic chemical therapy and how that may affect patient outcomes, said Axel Schnthal, PhD, of the University of Southern California Keck School of ...

Green Tea May Negate the Effects of a Common Cancer Therapy

... other natural supplements to complement their therapeutic regimens. We wanted to better understand how the compounds in green tea interact with a cytotoxic chemical therapy and how that may affect patient outcomes," said Axel Schonthal, Ph.D., of the University of Southern California Keck School of ...

New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110

... update any forward-looking statements, whether as a result of new information, future events or otherwise. (1) Haas C. et al. (2009). Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology , published online on January 19; PubMed ID: 19157637 ...

Gene therapy eliminates brain tumors through selective recruitment of immune cells

... of peripheral dendritic cells into the brain tumor and the subsequent activation of dendritic cells and stimulation of a specific anti-tumor cytotoxic T-cell mediated response." Building on more than 10 years of research in this area, the researchers used a combined gene therapeutic approach, ...
Other Contents
(Date:10/16/2014)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market announces ... the Smart Wallet, at the 13 th annual ... global conference on the intersection of technology and the ... , founder and publisher of the Strategic News Service™, ...
(Date:10/15/2014)... rapidly and to an unexpected extent. The outbreak does ... the virus shows a new disease dynamic in regions, ... reason, the German National Academy of Sciences Leopoldina, acatech ... the Union of the German Academies of Sciences and ... today. , In the statement the academies call for ...
(Date:10/14/2014)... – Like discriminating thieves, prostate cancer tumors scavenge and ... body. But such avarice may be a fatal weakness. ... way to kill prostate cancer cells by delivering a ... destroys the diseased cells brimming with the mineral, leaving ... two drugs already commercially available for other uses, could ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2
(Date:10/22/2014)... RESTON, Va. (PRWEB) October 22, 2014 ... Healthcare Innovation , which is dedicated to distribute ... efficiency of healthcare delivery worldwide announced the development ... in which patients expect when receiving healthcare. These ... definition for patient-centered care: “providing care that is ...
(Date:10/22/2014)... 2014 With the Affordable Care Act (ACA) ... the American Institutes for Research (AIR) finds that three out ... health insurance, but 42 percent say they are not likely ... signing up for coverage. , The AIR survey found wide ... able to calculate correctly how much they owe for a ...
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... October 22, 2014 Losing Weight Your Body’s ... is staring you in the face, it certainly can be ... do your body an extra favor by doing it the ... crash diets. Instead, listen to your body, exercise regularly, and ... is essential to losing weight; you need to exercise more ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2
Other TagsOther Tags